1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cystatin C Assay Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of kidney diseases and growing geriatric population
5.1.1.2. Progressive investments in healthcare infrastructures for renal disorders
5.1.2. Restraints
5.1.2.1. High development costs of cystatin C assays and incidences of product recalls
5.1.3. Opportunities
5.1.3.1. Advances in cystatin C assay testing
5.1.3.2. Emerging research for adoption of cystatin C assays as alternative to creatinine-based tests
5.1.4. Challenges
5.1.4.1. Dearth of skilled lab professionals and technical challenges associated with cystatin C assay
5.2. Market Segmentation Analysis
5.2.1. Product: Consumer preference cystatin C analyzer for diagnosis and monitoring conditions
5.2.2. Method: Expanding usage of enzyme-linked immunosorbent assay (ELISA) for cystatin C assays
5.2.3. Setting: Expanding usage of point-of-care setting for cystatin C assays
5.2.4. Sample Type: Significant role urine sample for cystatin C assay for measuring the amount of creatinine in a sample
5.2.5. Application: Increasing application of cystatin C assays for diagnosis of renal function
5.2.6. End-user: Expanding usage of cystatin C assays in academic research centers for studying biomarkers
5.3. Market Trend Analysis
5.3.1. Well-established healthcare infrastructure coupled with emphasis on commercializing Cystatin C Assay solutions in the Americas
5.3.2. Supportive government programs to reduce the burden of renal disorders in the Asia-Pacific region
5.3.3. Growing focus on developing and expanding novel cystatin C assays products in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Cystatin C Assay Market, by Product
6.1. Introduction
6.2. Analyzer
6.3. Kits
6.4. Reagents
7. Cystatin C Assay Market, by Method
7.1. Introduction
7.2. Chemiluminescence Immunoassay
7.3. Enzyme linked Immunosorbent Assay
7.4. Immunofluorescence Assay
7.5. Particle-enhanced Nephelometric Immunoassay
7.6. Particle-enhanced Turbidimetric Immunoassay
8. Cystatin C Assay Market, by Sample Type
8.1. Introduction
8.2. Blood
8.3. Urine
9. Cystatin C Assay Market, by Setting
9.1. Introduction
9.2. Laboratory Setting
9.3. Point of Care Setting
10. Cystatin C Assay Market, by Application
10.1. Introduction
10.2. Diagnosis Use
10.3. Research & Development
11. Cystatin C Assay Market, by End-user
11.1. Introduction
11.2. Academic Research Centers
11.3. Diagnostic Laboratories
11.4. Hospitals & Clinics
12. Americas Cystatin C Assay Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Cystatin C Assay Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Cystatin C Assay Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.2. Market Share Analysis, By Key Player
15.3. Competitive Scenario Analysis, By Key Player
15.3.1. Agreement, Collaboration, & Partnership
15.3.1.1. Renalytix Selects EVERSANA to Expand Commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes
15.3.1.2. Jana Care to Enter Collaboration with Roche to Develop and Distribute Blood Testing Platform to Improve Remote Care for Patients With Chronic Kidney and Heart Disease
15.3.1.3. Gentian Diagnostics ASA Signs Distribution Agreement for Cystatin C
15.3.2. New Product Launch & Enhancement
15.3.2.1. Bloom Diagnostics Launches New Kidney Test
15.3.3. Investment & Funding
15.3.3.1. Jana Care Raises USD 6 Million for Commercialisation of Self-Administered Blood Tests
15.3.3.2. Renalyse Closes a EUR 1 Million Funding Round with the Participation of GENESIS Ventures
15.3.4. Award, Recognition, & Expansion
15.3.4.1. LordsMed Announces the Launch of its First Pathology Centre in Maharashtra
15.3.4.2. New European Cystatin C Equation for eGFR May Be More Accurate
16. Competitive Portfolio
16.1. Key Company Profiles
16.1.1. Abbexa Limited
16.1.2. Abbott Laboratories
16.1.3. Abcam PLC
16.1.4. Advy Chemical Pvt. Ltd.
16.1.5. Agilent Technologies, Inc.
16.1.6. AOBIOUS Inc.
16.1.7. Arbor Assays Inc.
16.1.8. Aviva Systems Biology Corporation
16.1.9. BBI Solutions OEM Limited
16.1.10. Bio-Rad Laboratories, Inc.
16.1.11. Bio-Techne Corporation
16.1.12. Biorbyt Ltd
16.1.13. BioVendor – Laboratorní medicína a.s.
16.1.14. Boditech Med Inc.
16.1.15. Cepham Life Sciences, Inc.
16.1.16. Cusabio Technology LLC
16.1.17. DIALAB GmbH
16.1.18. DiaSys Diagnostic Systems GmbH
16.1.19. Diazyme Laboratories, Inc. by General Atomics
16.1.20. Eagle Biosciences, Inc.
16.1.21. Elabscience Biotechnology Inc.
16.1.22. Ethos Biosciences, Inc.
16.1.23. Eurolyser Diagnostica GmbH by Mars, Incorporated
16.1.24. F. Hoffmann-La Roche Ltd
16.1.25. Fapon Biotech Inc.
16.1.26. Fortress Diagnostics Ltd.
16.1.27. Gentian Diagnostics ASA
16.1.28. Getein Biotech, Inc.
16.1.29. ImmunoDiagnostics Limited
16.1.30. Kamiya Biomedical Company
16.1.31. Laboratory Corporation of America Holdings
16.1.32. Merck KGaA
16.1.33. Proteintech Group, Inc.
16.1.34. PZ CORMAY S.A.
16.1.35. Randox Laboratories Ltd.
16.1.36. RayBiotech, Inc.
16.1.37. Sekisui Diagnostics, LLC
16.1.38. Siemens Healthineers AG
16.1.39. Sino Biological, Inc.
16.1.40. Thermo Fisher Scientific Inc.
16.1.41. Tosoh Corporation
16.1.42. Weldon Biotech
16.1.43. Zhejiang Kangte Biotechnology Co., Ltd.
16.2. Key Product Portfolio
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing